Advanced search

Instruments

	Name		Stock exchange	Average volume	Price	Type
	CHRISTOPHER & BANKS CORPORATION	CBKCQ	OTC Markets	0	0.0001 USD	Stock

News (330)

Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	PR
Biogen expects to return to profit growth this year	Feb. 13	RE
Biogen fourth-quarter profit misses on Aduhelm exit costs	Feb. 13	RE
Biogen to Realign Resources for Alzheimer's Disease Franchise	Jan. 31	GL
Biogen to Realign Resources for Alzheimer's Disease Franchise	Jan. 31	AQ
Biogen : to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 19	PU
"LEQEMBI Intravenous Infusion"Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20	Dec. 14	AQ
Biogen : “LEQEMBI® Intravenous Infusion” (Lecanemab) for the Treatment of Alzheimer’s Disease to be Launched in Japan on December 20	Dec. 12	PU
Biogen : Q3 2023 Biogen Earnings Presentation	Nov. 08	PU
Biogen : Reports Q3 2023 Earnings	Nov. 08	PU
Biogen cuts annual profit forecast on persistent higher costs	Nov. 08	RE
EISAI PRESENTS NEW LEQEMBI INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD	23-10-26	AQ
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference	23-10-25	GL
EISAI PRESENTS NEW LEQEMBI® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE	23-10-25	PR
Eisai Co., Ltd. - LEQEMBI Intravenous Infusion Approved for the Treatment of Alzheimer's disease in Japan	23-09-26	AQ
Biogen Completes Acquisition of Reata Pharmaceuticals	23-09-26	GL
Biogen Completes Acquisition of Reata Pharmaceuticals	23-09-26	AQ
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan	23-09-25	AQ
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan	23-09-25	GL
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS	23-09-21	PU
Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023	23-09-06	CI
Biogen Appoints Jane Grogan as Head of Research	23-09-06	GL
Biogen Appoints Jane Grogan as Head of Research	23-09-06	AQ
Biogen : to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference	23-08-30	PU
First oral medicine for postpartum depression approved	23-08-07	AQ
Sage Therapeutics - FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder	23-08-07	AQ
Biogen, Sage face uphill battle with postpartum depression pill	23-08-07	RE
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder	23-08-04	BU
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder	23-08-04	AQ
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder	23-08-04	GL
Reata Pharmaceuticals : VOTING AND SUPPORT AGREEMENT - Form 8-K	23-07-31	PU
Biogen to acquire rare disease drugmaker for $7.3b	23-07-31	AQ
Reata Pharmaceuticals : Announces Biogen to Acquire Reata Pharmaceuticals	23-07-28	PU
Biogen to bulk up rare disease treatments with $7 billion Reata acquisition	23-07-28	AQ
Biogen to Acquire Reata Pharmaceuticals	23-07-28	GL
Biogen : Reports Second Quarter 2023 Results	23-07-25	PU
Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S - Form 8-K	23-07-25	PU
Biogen : Reports Q2 2023 Earnings	23-07-25	PU
Biogen : Q2 2023 Biogen Earnings Presentation	23-07-25	PU
Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace	23-07-25	RE
EISAI PRESENTS LATEST ANALYSIS OF LECANEMAB'S EFFECT ON BIOMARKER CHANGES AND SUBCUTANEOUS DOSING AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2023	23-07-20	AQ
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023	23-07-19	PR
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023	23-07-19	GL
EISAI - FDA GRANTS TRADITIONAL APPROVAL FOR LEQEMBI FOR THE TREATMENT OF ALZHEIMER'S DISEASE	23-07-07	AQ

1234NextSee all

Companies (2)

CHRISTOPHER & BANKS CORPORATION 3 857 $

CB Wind-Down Corp, formerly Christopher & Banks Corporation, is not engaged in any business operations. ...

PT PANCA ANUGRAH WISESA TBK 7 M $

PT Panca Anugrah Wisesa Tbk is an Indonesia-based company, which offers luxury products, such as living rooms and houses, kitchen and sanitary appliances, as well as luxurious interior appliances. The Company is mainly focused on importing marble and gran ...

Insiders

Christopher Viehbacher

Chris Viehbacher (born 1960) is a German-Canadian businessman. He served as the Chief Executive Officer of Sanofi and Chairman of Genzyme until 29 October 2014.

Biography
Early life
Chris Viehbacher was born on March 26, 1960. He graduated from Queen's University in Kingston, Ontario, Canada. He is a certified public accountant, and he speaks French, German and English.

Career
He started his career at PriceWaterhouseCoopers. In 1988, he joined GlaxoSmithKline, where he worked for the next twenty years, including in France for ten years. Until October 29 2014, he served as CEO of Sanofi and Chairman of Genzyme.

He was Chairman of the Pharmaceutical Research and Manufacturers of America from December 2010 to April 2012. He has been Chair of the CEO Roundtable on Cancer since February 2011. He is a member of The Business Roundtable and the International Business Council. He sits on the Board of Directors of Research America and the Burroughs Wellcome Fund. He will serve as President of the European Federation of Pharmaceutical Industries and Associations from June 2013 onwards.

In 2003, he became a Knight in the Legion of Honour. In 2012, he received the Pasteur Foundation Award. He sits on the Board of Visitors of the Fuqua School of Business at Duke University.

Personal life
He is married and has three children.

Source @ Wikipedia

Alfons Viehbacher

Christopher David Christopher

Christopher G. Christopher

Christopher Christopher

Christopher Christopher Theis

Christopher Christopher Ivan

Christopher

No results for this search

Stock Market
Advanced search
Christopher Viehbacher